Early ECG Prediction of Multi-system Disease Cohort Establishment and Follow Up

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorRenJi Hospital

About this trial

This registered multicenter study aims to investigate the diagnostic efficacy of artificial intelligence-enhanced electrocardiography (AI-ECG) in detecting multi-system diseases. The research will utilize prospectively collected data from inpatient, emergency, and outpatient populations to develop ECG-based diagnostic, screening, and predictive models for multi-system diseases.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients who visited the study hospital.

Patients included should have both ECG data and discharge diagnosis codes (ICD-10) for inpatients and emergency patients.

Disqualifiers

None

Trial population

All patients undergoing ECG examinations

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • ECG screening

    Other intervention

    Each subject is subjected to ECG assessment.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Multi-system disease predicting based on ECG

Evaluating the effectiveness of ECG in predicting diseases across various systems, such as circulatory system diseases, respiratory system diseases, digestive system diseases, nervous system diseases, urogenital system diseases, endocrine and nutritional/metabolic system diseases, hematological diseases, infectious and parasitic diseases, tumors, and mental and behavioral disorders. This study initially uses the ICD-10 coding system for preliminary screening of target diseases. Subsequently, a committee of multidisciplinary clinical experts conducts a systematic review of candidate diseases based on the ICD-10 coding system framework, including the applicability of diagnostic criteria, the accuracy of ICD-10 classification, the reasonableness of exclusion criteria, and the assessment of the level of evidence.

Time frame
1 month

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.